Inactive Instrument

Spring Bank Pharmaceuticals, Inc.

Equities

SBPH

US8494311017

Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019

February 14, 2020 at 06:21 am EST

Spring Bank Pharmaceuticals, Inc. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced operating loss was USD 33.021 million compared to USD 28.470 million a year ago. Net loss was USD 24.097 million compared to USD 22.854 million a year ago. Basic loss per share from continuing operations was USD 1.46 compared to USD 1.59 a year ago. Diluted loss per share from continuing operations was USD 1.46 compared to USD 1.88 a year ago.

Latest news about Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals, Inc. has Changed its Name to F-star Therapeutics, Inc	20-11-20	CI
F-Star Therapeutics Limited completed the acquisition of Spring Bank Pharmaceuticals, Inc. in a reverse merger transaction.	20-11-19	CI
Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-03	CI
Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-10	CI
Transcript : Spring Bank Pharmaceuticals, Inc., F-Star Therapeutics Limited - M&A Call	20-07-30
F-Star Therapeutics Limited entered into a definitive agreement to acquire Spring Bank Pharmaceuticals, Inc. for $90.6 million in a reverse merger transaction.	20-07-28	CI
Spring Bank Pharmaceuticals, Inc.(NasdaqCM:SBPH) dropped from Russell Microcap Value Index	20-06-26	CI
Spring Bank Pharmaceuticals, Inc.(NasdaqCM:SBPH) dropped from Russell Microcap Growth Index	20-06-26	CI
Spring Bank Pharmaceuticals, Inc.(NasdaqCM:SBPH) dropped from Russell Microcap Index	20-06-26	CI
Transcript : Spring Bank Pharmaceuticals, Inc. - Shareholder/Analyst Call	20-06-24
Spring Bank Pharmaceuticals, Inc. Advances IV SB 11285 Clinical Program	20-06-03	CI
Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-07	CI
Spring Bank Pharmaceuticals, Inc. Announces Management Changes	20-04-13	CI
Spring Bank Pharmaceuticals, Inc. Announces New Clinical Collaboration with Roche	20-02-25	CI
Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-02-14	CI
Spring Bank Pharmaceuticals, Inc. Discontinues Development of Inarigivir for the Treatment of HBV	20-01-29	CI
Transcript : Spring Bank Pharmaceuticals, Inc. - Special Call	19-12-26
Spring Bank Pharmaceuticals, Inc Announces Update on Phase 2B Catalyst Trials	19-12-26	CI
Spring Bank Announces Dosing of Patients in Phase 1 Clinical Trial of IV-Administered STING Agonist, SB 11285	19-11-20	CI
Transcript : Spring Bank Pharmaceuticals, Inc. - Special Call	19-11-11
Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-07	CI
Spring Bank Pharmaceuticals, Inc. Announces Interim Top-Line Results from the First Cohort of the Phase 2 Trial Evaluating Low-Dose Inarigivir Plus Vemlidy® in Chronic Hepatitis B Patients	19-10-17	CI
Yale Cancer Center to Present on the Synergistic Relationship Between Intravenously-Administered SB 11285, Spring Bank’S Sting Agonist Development Compound, and Radiation Therapy in Cancer at the 2019 ASTRO Annual Meeting	19-09-17	CI
Spring Bank Pharmaceuticals, Inc. and Sperovie Biosciences, Inc. Entered into Loan and Security Agreement	19-09-04	CI
Spring Bank Pharmaceuticals, Inc. Enters into Research Agreement with the University of Texas Southwestern Medical School	19-08-06	CI

Chart Spring Bank Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics for the treatment of viral infections, inflammatory diseases and cancers using its small molecule nucleotide platform. The Company is developing its product inarigivir soproxil (inarigivir), for the treatment of chronic hepatitis B virus (HBV). The Company's inarigivir selectively activates within infected hepatic cells the cellular protein, retinoic acid-inducible gene 1 (RIG-I), to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company also developing a second STING (STimulator of INterferon Genes) agonist product candidate, SB 11285, which is an immunotherapeutic agent for the potential treatment of selected cancers. The Company lead product is inarigivir.

Sector

More about the company